We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
Read MoreHide Full Article
Key Takeaways
Axsome dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for smoking cessation.
SUMMIT study will compare AXS-05, bupropion and placebo in adult smokers over approximately 12 weeks.
The study's primary endpoint is smoking abstinence at the end of the 12-week treatment period.
Axsome Therapeutics (AXSM - Free Report) announced that it has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for the treatment of smoking cessation.
The randomized, double-blind, placebo-controlled phase III SUMMIT study is designed to assess the safety and efficacy of AXS-05 for treating smoking cessation in adults. In the study, active smokers will be randomized to receive AXS-05, bupropion, or placebo in a 1:1:1 ratio for approximately 12 weeks.
The primary endpoint of the SUMMIT study is to check smoking abstinence at the end of the 12-week treatment period.
Axsome currently markets AXS-05 under the trade name Auvelity in the United States for the treatment of major depressive disorder (MDD).
In April 2026, the FDA approved Auvelity for the treatment of agitation associated with dementia due to Alzheimer’s disease. The approval was based on data from phase III ADVANCE-1 and ACCORD-2 studies.
Year to date, shares of Axsome have increased 8.7% compared with the industry’s rise of 9.7%.
Image Source: Zacks Investment Research
Auvelity Drives Axsome’s Revenue Surge
Axsome’s lead drug, Auvelity, has been witnessing strong uptake. The drug has played an instrumental role in driving the company’s top line since its approval and launch in the United States in 2022. Sales of the drug have been rising consistently owing to strong demand.
Auvelity generated sales worth $333 million in the first half of 2026, increasing 54.2% year over year in the United States. The drug’s sales are being driven by prescription growth and higher volumes and the momentum is likely to continue in the rest of 2026.
The successful commercialization of Auvelity in additional indications would help the drug address a broader patient population and drive sales further in future quarters.
Besides Auvelity, Axsome’s narcolepsy drug, Sunosi (solriamfetol), is also generating incremental sales and aiding the top line. Axsome acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (JAZZ - Free Report) .
The acquisition of Sunosi from Jazz diversified the company’s commercial portfolio.
Sunosi generated sales worth $66.5 million in the first half of 2026, reflecting an increase of 25.5% year over year. The drug has become an important revenue driver for Axsome.
Axsome’s newest product, Symbravo, was approved by the FDA for the acute treatment of migraine with or without aura in adults in January 2025. The drug was launched in the United States in June 2025. Symbravo recorded sales worth $6.3 million in the first six months of 2026. The approval further diversified Axsome’s commercial portfolio.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 10.5% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Anika Therapeutics’ 2026 earnings per share have risen from 41 cents to $1.05, while estimates for 2027 have increased from 46 cents to 95 cents during the same time. ANIK’s shares have surged 117.2% year to date.
Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.
View the Zacks #1 Rank List
Image: Bigstock
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
Key Takeaways
Axsome Therapeutics (AXSM - Free Report) announced that it has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for the treatment of smoking cessation.
The randomized, double-blind, placebo-controlled phase III SUMMIT study is designed to assess the safety and efficacy of AXS-05 for treating smoking cessation in adults. In the study, active smokers will be randomized to receive AXS-05, bupropion, or placebo in a 1:1:1 ratio for approximately 12 weeks.
The primary endpoint of the SUMMIT study is to check smoking abstinence at the end of the 12-week treatment period.
Axsome currently markets AXS-05 under the trade name Auvelity in the United States for the treatment of major depressive disorder (MDD).
In April 2026, the FDA approved Auvelity for the treatment of agitation associated with dementia due to Alzheimer’s disease. The approval was based on data from phase III ADVANCE-1 and ACCORD-2 studies.
Year to date, shares of Axsome have increased 8.7% compared with the industry’s rise of 9.7%.
Image Source: Zacks Investment Research
Auvelity Drives Axsome’s Revenue Surge
Axsome’s lead drug, Auvelity, has been witnessing strong uptake. The drug has played an instrumental role in driving the company’s top line since its approval and launch in the United States in 2022. Sales of the drug have been rising consistently owing to strong demand.
Auvelity generated sales worth $333 million in the first half of 2026, increasing 54.2% year over year in the United States. The drug’s sales are being driven by prescription growth and higher volumes and the momentum is likely to continue in the rest of 2026.
The successful commercialization of Auvelity in additional indications would help the drug address a broader patient population and drive sales further in future quarters.
Besides Auvelity, Axsome’s narcolepsy drug, Sunosi (solriamfetol), is also generating incremental sales and aiding the top line. Axsome acquired U.S. rights to Sunosi from Jazz Pharmaceuticals (JAZZ - Free Report) .
The acquisition of Sunosi from Jazz diversified the company’s commercial portfolio.
Sunosi generated sales worth $66.5 million in the first half of 2026, reflecting an increase of 25.5% year over year. The drug has become an important revenue driver for Axsome.
Axsome’s newest product, Symbravo, was approved by the FDA for the acute treatment of migraine with or without aura in adults in January 2025. The drug was launched in the United States in June 2025. Symbravo recorded sales worth $6.3 million in the first six months of 2026. The approval further diversified Axsome’s commercial portfolio.
AXSM’s Zacks Rank & Stocks to Consider
Axsome currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) and Anika Therapeutics (ANIK - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 10.5% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Anika Therapeutics’ 2026 earnings per share have risen from 41 cents to $1.05, while estimates for 2027 have increased from 46 cents to 95 cents during the same time. ANIK’s shares have surged 117.2% year to date.
Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.